Sep 23, 2024
MediSieve Selected to Present at ACCESS CHINA Partnering Forum
CEO George Frodsham will showcase their groundbreaking Magnetic Blood Filtration technology to over 500 healthcare companies and venture capitalists.
LONDON, 23 September 2024 – MediSieve, the pioneering company behind Magnetic Blood Filtration technology, is delighted to announce that it has been selected to present at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase. The event is scheduled to take place online via Zoom webinar on 24th, 25th, and 27th September 2024.
The ACCESS CHINA Partnering Forum is a prestigious platform that brings together over 500 healthcare companies and venture capitalists from around the globe. It offers a unique opportunity for innovative biotech and pharmaceutical companies to showcase their cutting-edge products and technologies to a wide-reaching audience.
Dr George Frodsham, Founder and CEO of MediSieve, will be presenting the company's latest advancements in Magnetic Blood Filtration technology. This technology has the potential to revolutionise the treatment of blood-borne diseases by directly removing harmful substances from the bloodstream.
"Being selected to present at the ACCESS CHINA Partnering Forum is a significant honour for us," said Dr Frodsham. "We are eager to share our groundbreaking work with an international audience and explore potential collaborations that could accelerate the impact of our technology on global healthcare."
Attendees of the forum will have the chance to learn more about MediSieve's innovative approach and discuss partnership opportunities. The event facilitates efficient networking and collaboration within the biotech and pharmaceutical industries.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Capture System captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is an innovative BioTech company based in the White City Innovation District of West London. A spin-off from University College London, MediSieve is dedicated to developing its Magnetic Blood Filtration technology, a transformative approach to physically removing or isolating substances from the bloodstream. The company continues to seek investment and partnerships to advance its technology for broader applications in healthcare.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
